Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of QLC7401 in heterozygous familial hypercholesterolemia with inadequate lipid control on stable background therapy
CTR20260300Phase 3Active
- Sponsor
- Suzhou Ribo Life Science Co., Ltd.
- Start
- Apr 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in familial hypercholesterolemia (FH) comparing QLC7401 with Placebo (2 arms). Primary endpoint: Percent change from baseline in LDL-C at Day 330. Started Apr 2026; status: active.
02
Drugs
rbd7022
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on CTR20260300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260300.